NO20091830L - Spiro-piperidinderivater som VIa reseptorantagonister - Google Patents

Spiro-piperidinderivater som VIa reseptorantagonister

Info

Publication number
NO20091830L
NO20091830L NO20091830A NO20091830A NO20091830L NO 20091830 L NO20091830 L NO 20091830L NO 20091830 A NO20091830 A NO 20091830A NO 20091830 A NO20091830 A NO 20091830A NO 20091830 L NO20091830 L NO 20091830L
Authority
NO
Norway
Prior art keywords
spiro
receptor antagonists
piperidine derivatives
via receptor
present
Prior art date
Application number
NO20091830A
Other languages
English (en)
Norwegian (no)
Inventor
Patrick Schnider
Hasane Ratni
Caterina Bissantz
Christophe Grundschober
Mark Rogers-Evans
Rafaello Masciadri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20091830L publication Critical patent/NO20091830L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20091830A 2006-12-07 2009-05-11 Spiro-piperidinderivater som VIa reseptorantagonister NO20091830L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125634 2006-12-07
PCT/EP2007/062985 WO2008068185A1 (en) 2006-12-07 2007-11-29 Spiro-piperidine derivatives as via receptor antagonists

Publications (1)

Publication Number Publication Date
NO20091830L true NO20091830L (no) 2009-07-06

Family

ID=39295880

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091830A NO20091830L (no) 2006-12-07 2009-05-11 Spiro-piperidinderivater som VIa reseptorantagonister

Country Status (21)

Country Link
US (3) US20080146568A1 (pt)
EP (1) EP2102207B1 (pt)
JP (1) JP2010511661A (pt)
KR (1) KR101050568B1 (pt)
CN (1) CN101547923A (pt)
AR (1) AR064135A1 (pt)
AT (1) ATE469900T1 (pt)
AU (1) AU2007328995B2 (pt)
BR (1) BRPI0720004A2 (pt)
CA (1) CA2670674A1 (pt)
CL (1) CL2007003482A1 (pt)
DE (1) DE602007006990D1 (pt)
ES (1) ES2344131T3 (pt)
IL (1) IL198544A (pt)
MX (1) MX2009005504A (pt)
NO (1) NO20091830L (pt)
PE (1) PE20081252A1 (pt)
RU (1) RU2009119394A (pt)
TW (1) TW200838518A (pt)
WO (1) WO2008068185A1 (pt)
ZA (1) ZA200903496B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077810A2 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
EP2722333A1 (en) 2008-04-29 2014-04-23 Novartis AG Spiro-indole derivatives for the treatment of parasitic diseases.
AU2015345102A1 (en) * 2014-11-14 2017-03-30 F. Hoffmann-La Roche Ag Spiro-thiazolones
EP3414247B1 (en) * 2016-02-08 2021-04-21 F. Hoffmann-La Roche AG Spiroindolinones as ddr1 inhibitors
US10538530B2 (en) * 2017-09-05 2020-01-21 Blackthorn Therapeutics, Inc. Vasopressin receptor antagonists and products and methods related thereto

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3370091A (en) * 1964-06-15 1968-02-20 Hoffmann La Roche 2 aminobenzhydrylhalides
US3531467A (en) * 1966-12-23 1970-09-29 Hoffmann La Roche Process for the preparation of 2,3,4,5-tetrahydro - 5 - aryl - 1h - 1,4 - benzodiazepine derivatives
US4209625A (en) * 1977-04-21 1980-06-24 American Hoechst Corporation Spiro[indoline-3,4'-piperidine]s
DE3818830A1 (de) * 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
EP0450761A1 (en) * 1990-03-02 1991-10-09 Merck & Co. Inc. Spirocyclic oxytocin antagonists
DK78692D0 (da) 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
WO1994007496A1 (en) 1992-10-07 1994-04-14 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5670509A (en) 1993-09-27 1997-09-23 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
IT1271026B (it) 1994-10-21 1997-05-26 Isagro Ricerca Srl Derivati dell'acido b-amminopropionico ad attivita' fungicida
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
SK77298A3 (en) 1995-12-14 1999-01-11 Merck & Co Inc Nonpeptide derivatives, pharmaceutical composition containing them and their use
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
CO5150201A1 (es) 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
ATE255578T1 (de) 2000-05-12 2003-12-15 Solvay Pharm Bv Piperazin- und piperidinverbindungen
DK1325011T3 (da) 2000-09-29 2004-08-16 Lilly Co Eli Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
ES2303558T3 (es) 2001-11-27 2008-08-16 F. Hoffmann-La Roche Ag Derivados de benzotiazol.
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
US20040152741A1 (en) 2002-09-09 2004-08-05 Nps Allelix Corporation Arylglycine derivatives and their use as glycine transport inhibitors
AU2003263155A1 (en) 2002-09-20 2004-04-08 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
US7582761B2 (en) 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2004069809A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7244852B2 (en) * 2003-02-27 2007-07-17 Abbott Laboratories Process for preparing 2-methylpyrrolidine and specific enantiomers thereof
EP1618090A1 (en) * 2003-04-11 2006-01-25 Novo Nordisk A/S 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
EP1682136A4 (en) 2003-11-04 2009-06-03 Elixir Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND CORRESPONDING USES THEREOF
BRPI0417267A (pt) * 2003-12-22 2007-04-17 Pfizer derivados de triazol como antagonistas de vasopressina
JP2007516298A (ja) 2003-12-23 2007-06-21 アリーナ ファーマシューティカルズ， インコーポレイテッド 新規なスピロインドリンまたはスピロイソキノリン化合物、それらの使用方法および組成物
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
CN1993323B (zh) 2004-08-05 2011-04-20 霍夫曼-拉罗奇有限公司 吲哚，吲唑或二氢吲哚衍生物
EP1802623A1 (en) 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
CN100551006C (zh) * 2004-10-13 2009-10-14 索尼株式会社 再现装置、成像装置以及屏幕显示方法
CA2608718A1 (en) 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4-triazole derivatives as vasopressin antagonists
US8190027B2 (en) 2006-07-12 2012-05-29 Tellabs Operations, Inc. Multifunctional and reconfigurable optical node and optical network
KR100974967B1 (ko) * 2005-07-14 2010-08-09 에프. 호프만-라 로슈 아게 Ｖ1ａ 수용체 길항물질로서의인돌-3-카본일-스피로-피페리딘 유도체
JP2009507800A (ja) 2005-09-09 2009-02-26 ユーロ−セルティーク エス．エイ． 縮合およびスピロ環化合物ならびにその使用
WO2008077810A2 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
DK2125827T3 (da) * 2006-12-29 2010-12-20 Hoffmann La Roche Azaspiroderivater
JP2010515700A (ja) * 2007-01-12 2010-05-13 エフ．ホフマン−ラ ロシュ アーゲー スピロピペリジングリシンアミド誘導体

Also Published As

Publication number Publication date
KR101050568B1 (ko) 2011-07-19
EP2102207B1 (en) 2010-06-02
EP2102207A1 (en) 2009-09-23
AR064135A1 (es) 2009-03-18
US20080139553A1 (en) 2008-06-12
TW200838518A (en) 2008-10-01
IL198544A0 (en) 2010-02-17
CN101547923A (zh) 2009-09-30
MX2009005504A (es) 2009-06-03
ATE469900T1 (de) 2010-06-15
BRPI0720004A2 (pt) 2013-12-17
RU2009119394A (ru) 2011-01-20
US8202993B2 (en) 2012-06-19
CA2670674A1 (en) 2008-06-12
WO2008068185A1 (en) 2008-06-12
US20080139554A1 (en) 2008-06-12
ES2344131T3 (es) 2010-08-18
KR20090079255A (ko) 2009-07-21
AU2007328995B2 (en) 2012-04-26
AU2007328995A1 (en) 2008-06-12
JP2010511661A (ja) 2010-04-15
US20080146568A1 (en) 2008-06-19
PE20081252A1 (es) 2008-09-04
ZA200903496B (en) 2010-03-31
CL2007003482A1 (es) 2008-07-04
IL198544A (en) 2012-06-28
DE602007006990D1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
NO20092342L (no) Azaspiroderivativater
NO20091766L (no) Spiro-piperidinderivater
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20092149L (no) Spiro-piperidinderivater
NO20073719L (no) Kjemiske forbindelser
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20082709L (no) Kjemiske forbindelser
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20085100L (no) Nye forbindelser
NO20091683L (no) Kjemiske forbindelser
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
NO20090760L (no) Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet
NO20055688L (no) Organiske forbindelser
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
NO20071314L (no) Peptidiske vasopressinreseptoragonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application